Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SDI-118
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Acquisition
AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio
Details : AbbVie has beefed up its neuro pipeline by acquiring Belgium-based Syndesi Therapeutics. This acquisition gives AbbVie access to Syndesi’s lead candidate SDI-118, a small molecule that is under evaluation to treat Alzheimer’s disease and major depres...
Brand Name : SDI-118
Molecule Type : Small molecule
Upfront Cash : $130.0 million
March 01, 2022
Lead Product(s) : SDI-118
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : AbbVie Inc
Deal Size : $1,000.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?